Yearly Archives : 2013

Now available, Atrial Fibrillation video demonstration of the Epiomic database

With the Atrial Fibrillation video example, you will see firsthand the intuitive customer interface that makes it simple to navigate through the site and the ease in changing the selection criteria of age, gender or outlook period. With an extensive coverage in terms of distinct disease and sub-populations, Epiomic will…

Can rare diseases be a viable option for the pharma industry?

In this article, Christopher Ehinger questions whether rare diseases are a viable option for the pharma industry. He looks at the total number of approvals and orphan drug designations in the US since the Orphan Drug Act of 1983 and the factors driving pharma to invest its research and development budgets into discovering orphan drugs.   Background Rare…

Defining patient populations is a key trend shaping the pharma industry

Christopher Ehinger of Black Swan Analysis explores one of the key trends in the pharma industry at the moment: defining patient populations. He believes that in order to be successful in the future, the industry needs to have a better understanding of the patient populations for each individual disease. (Continued from “Enablers of drug innovation…